Celldex Therapeutics, Inc. (CLDX)
NASDAQ: CLDX · Real-Time Price · USD
26.98
+0.58 (2.20%)
Nov 21, 2024, 1:44 PM EST - Market open
Celldex Therapeutics Employees
Celldex Therapeutics had 160 employees as of December 31, 2023. The number of employees increased by 12 or 8.11% compared to the previous year.
Employees
160
Change (1Y)
12
Growth (1Y)
8.11%
Revenue / Employee
$62,350
Profits / Employee
-$962,981
Market Cap
1.79B
Employees Chart
Related Stocks
Company Name | Employees |
---|---|
Fortrea Holdings | 18,000 |
Integra LifeSciences Holdings | 3,946 |
NovoCure | 1,453 |
10x Genomics | 1,259 |
AtriCure | 1,200 |
GoodRx Holdings | 694 |
Clover Health Investments | 552 |
Immunocore Holdings | 497 |
CLDX News
- 1 day ago - Celldex Announces First Patient Dosed in Phase 1 Healthy Volunteer Study of CDX-622, a Bispecific Antibody, for the Treatment of Inflammatory Diseases - GlobeNewsWire
- 9 days ago - Celldex Therapeutics to Present at Upcoming Investor Conferences - GlobeNewsWire
- 14 days ago - Celldex Reports Third Quarter 2024 Financial Results and Provides Corporate Update - GlobeNewsWire
- 16 days ago - Celldex Therapeutics' Strong Cash Runway Supports Barzolvolimab's Path To Market - Seeking Alpha
- 25 days ago - Celldex Announces Barzolvolimab Met All Primary and Secondary Endpoints with High Statistical Significance in Positive Phase 2 Study in Chronic Inducible Urticaria - GlobeNewsWire
- 27 days ago - Celldex Announces Upcoming Late Breaking Oral Presentation of 12 Week Results from Barzolvolimab Phase 2 Study in Chronic Inducible Urticaria at ACAAI 2024 - GlobeNewsWire
- 2 months ago - Celldex Therapeutics Presents Landmark 52 Week Results from Barzolvolimab Phase 2 Study in Chronic Spontaneous Urticaria at EADV 2024 - GlobeNewsWire
- 2 months ago - Celldex Announces Upcoming Late Breaking Oral Presentation of 52 Week Results from Barzolvolimab Phase 2 Study in Chronic Spontaneous Urticaria at EADV Congress 2024 - GlobeNewsWire